The grades of 5 Pharmaceuticals stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.

Cempra, Inc. (CEMP) is seeing ratings go up from a D last week to a B this week. Cempra, Inc. manufactures and markets pharmaceutical products. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of CEMP stock.

This is a strong week for Assembly Biosciences, Inc. (ASMB). The company’s rating climbs to B from the previous week’s D. For more information, get Portfolio Grader’s complete analysis of ASMB stock.

Aratana Therapeutics, Inc. (PETX) boosts its rating from a C to a B this week. The company also gets A’s in sales growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of PETX stock.

The rating of NovaBay Pharmaceuticals, Inc. (NBY) moves up this week, rising from a C to a B. NovaBay Pharmaceuticals, Inc. develops product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of NBY stock.

This week, ContraVir Pharmaceuticals, Inc.’s (CTRV) ratings are up from a D last week to a B. For more information, get Portfolio Grader’s complete analysis of CTRV stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.